MedPath

Transcatheter Versus Standard Surgical Mitral Valve Operation for Secondary Mitral Regurgitation

Conditions
Severe Mitral Valve Regurgitation (Disorder)
Interventions
Procedure: Mitral Valve Replacement
Device: Trancatheter Edge to Edge Repair
Procedure: Restrictive Mitral Annuloplastie/Subvalvular Repair
Procedure: Restrictive Mitral Annuloplastie
Registration Number
NCT05090540
Lead Sponsor
Centre Cardiologique du Nord
Brief Summary

The mechanical intervention is treating secondary mitral regurgitation (SMR) which may be performed using the standard open surgical approach or transcatheter edge to edge repair (TEER). The key question of this study is to establish the difference in left ventricular reverse remodeling after adjustment for death, as assessed by means of the left ventricular end-systolic dimension(LVESD), all-cause and cause-specific (cardiac vs noncardiac) mortality in patients who received the TEER vs the standard surgical procedure for SMR.

Detailed Description

The target population enrolled in the registry includes patients with moderate to severe secondary mitral regurgitation due to cardiomyopathy of either ischemic or non-ischemic etiology who have had TEER or standard surgical procedure of their mitral valves with or without CABG. Individuals were adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, mitral regurgitation, and heart failure. Patients enrolled in the studies were NYHA functional class II, III, or outpatient NYHA IV.

Four groups of patients are included in the study. Patients who were managed with TEER, patients who received mitral valve replacement and recipients of mitral valve repair who underwent surgery with the use of restrictive annuloplasty alone or combined with subvalvular repair. Four groups of patients are included in the study. Patients who were managed with TEER, patients who received mitral valve replacement, and those who received mitral valve repair who underwent surgery with the use of restrictive annuloplasty alone or combined with subvalvular repair

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Adult
  • Ischemic NoIschemic cardiomyopathy
  • EROA> 0,2 cm2 or Regurgitant Volume > 30 ml (ESC guidelines).
  • EROA ≥ 0.4 cm2 with tethering (ACC/AHA)
  • MR Grade 3/4
  • Eligible for TEE, surgical repair and replacement of mitral valve
  • Coronary artery disease with or without the need for coronary revascularization
  • Average value LVEDD 62 mm LVEF 42%
Exclusion Criteria
  • Pediatric
  • Any echocardiographic evidence of structural (chordal or leaflet) mitral-valve disease
  • ruptured papillary

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Mitral Valve ReplacementMitral Valve ReplacementMitral-valve replacement includes complete preservation of the subvalvular apparatus to avoid dilation of the left ventricle over time. The technique of preservation, type of prosthetic valve implanted, and technique of suture placement has been chosen according to the preference of the surgeons. In SMR due to ischemic cardiomyopathy, CABG operation(Revascularization) is required
Transcatheter Edge to Edge RepairTrancatheter Edge to Edge RepairTEER procedure is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of MV. If the use of one MitraClip device does not result in sufficient reduction in mitral regurgitation, a second MitraClip device may be used to reduce MR optimizing the procedure.
Restrictive Mitral Annuloplastie Plus Subvalvular RepairRestrictive Mitral Annuloplastie/Subvalvular RepairRMA may be associated with the use of a subvalvular repair (SVR). The SVR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation. In patients who received SVR due to ischemic cardiomyopathy CABG operation is required
Restrictive Mitral AnnuloplastyRestrictive Mitral AnnuloplastieRMA may be performed with the use of complete rigid or semi-rigid annuloplasty ring which has been downsized for the annulus diameter. Since patients who received RMA have coronary artery lesions, a CABG operation is useful to ensure favorable remodeling of the left ventricle.
Primary Outcome Measures
NameTimeMethod
Left Ventricular Reverse Remodelling5 years

The primary end point of the study is the degree of left ventricular reverse remodeling, as assessed by means of the left ventricular end systolic dimension on the basis of transthoracic echocardiography

Secondary Outcome Measures
NameTimeMethod
Overall Mortality5 years

The secondary endpoint of the study is the evaluation of overall mortality

Cardiac Death5 years

The secondary endpoint of the study is the evaluation of cardiac death

Major Adverse Cardiac or Cerebrovascular Events (MACCE)5 years

Composite of major adverse cardiac or cerebrovascular events (rate of death, stroke, subsequent mitral valve surgery, hospitalization for heart failure, or an increase in New York Heart Association class higher than one), serious adverse events, recurrent mitral regurgitation, quality of life, and rehospitalization.

Echocardiographic Parameter Changes (LVEF)5 years

Changes from baseline parameters including left ventricular ejection fraction

Echocardiographic Parameter Changes (recurrence)5 years

Recurrent moderate-to-severe mitral regurgitation after intervention

Echocardiographic Parameter Changes (LVEDD)5 years

Changes from baseline Left Ventricular End Diastolic Diameter

Echocardiographic Parameter Changes (Mitral Valve tenting area and height)5 years

Changes from baseline tenting area and height

Echocardiographic Parameter Changes (Pulmonary artery systolic pressure)5 years

Changes from baseline pulmonary artery systolic pressure

Echocardiographic Parameter Changes (anteroposterior mitral valve annular diameter)5 years

Changes from baseline anteroposterior mitral valve annular diameter

Echocardiographic Parameter Changes ( interpapillary distance)5 years

Changes from baseline distance between papillary muscles

Trial Locations

Locations (2)

Francesco Nappi

🇫🇷

Saint Denis, France

Centre Cardiologique Du Nord

🇫🇷

Saint Denis, France

© Copyright 2025. All Rights Reserved by MedPath